Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.
View Top Employees from Finch TherapeuticsWebsite | http://www.finchtherapeutics.com |
Employees | 76 (76 on RocketReach) |
Founded | 2014 |
Industry | Biotechnology Research, Drug Discovery, Biotechnology |
Web Rank | 4 Million |
Keywords | Finch Therapeutics, Finch Therapeutics Group, Zain Kassam, Finch Microbiome Compnay, Finch Therapeutics Somerville Ma |
Looking for a particular Finch Therapeutics employee's phone or email?
Marc Blaustein is the Chief Operations Officer and Principal Financial Officer of Finch Therapeutics.
76 people are employed at Finch Therapeutics.
Finch Therapeutics is based in Somerville, Massachusetts.